A study published in Neuron, led by researchers at the University of Alabama at Birmingham with colleagues at Rush University Medical Center in Chicago and SUNY Upstate Medical Center in Syracuse, addresses one of the long-standing puzzles in Alzheimer's research: how tau tangles move from one region of the brain to another. The team reports evidence that targeting tau while it is in transit could be a viable route to slowing or preventing the disease's advance.
Tau is a protein found inside neurons, where it normally acts as scaffolding that supports the cell's internal structure. In Alzheimer's disease, tau proteins begin sticking to one another, forming the clumps known as neurofibrillary tangles. Those clumps impair how neurons function and eventually kill them. The pattern is consistent enough that the further tau spreads through the brain, the more memory loss follows - but the mechanism carrying it along the brain's network has remained unclear.
That gap matters because it shapes what a drug can realistically do. Tau is one of two proteins central to Alzheimer's, alongside the amyloid-beta plaques that accumulate outside cells, and both disrupt communication between brain cells and drive cell damage and death. If the route tau uses to travel can be identified and blocked, treatment could in principle halt the disease where it is rather than only addressing damage already done.
Alzheimer's remains the most common cause of dementia, affecting millions of families worldwide and carrying a heavy emotional and economic burden. Work like this is at the stage of explaining biology rather than delivering therapy, but understanding the spread of tau is a prerequisite for any drug designed to interrupt it.